Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shinpoong Pharmaceutical Co., Ltd. (019170.KS)
Seoul, KR
Shinpoong Pharmaceutical Co., Ltd. is a South Korean company that manufactures and distributes a broad spectrum of pharmaceutical products. Its portfolio includes both cephalosporin and penicillin antibiotics, alongside other finished medications. The company also produces active pharmaceutical ingredients (APIs) and offers specialized drugs such as Pyramax, an anti-malarial treatment, as well as therapies for hypercholesterolemia, knee osteoarthritis, shoulder periarthritis, and surgical adhesion prevention. Furthermore, they market various over-the-counter (OTC) products. Founded in 1962 and headquartered in Seoul, South Korea, Shinpoong Pharmaceutical extends its market reach internationally, exporting its goods to roughly 50 countries.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.30% | -3.63% | -22.64% | -14.38% | -19.44% | -21.81% | +38.85% | -35.88% | -83.41% | +7.92% | +5,180.16% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.2% Q1'26: -1.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+149.7% ★ Q1'26: +125.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+4.0% Q1'26: +10.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+6.1% Q1'26: -0.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+5.6% Q1'26: -0.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+7.7% Q1'26: +8.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.18× ★ Q1'26: 5.93× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
|---|---|
| Revenue |
187.39B
est: 180.00M (+104,005.1%)
|
| EBITDA |
19.12B
est: -6.86M (+278,800.7%)
|
| EBIT |
9.46B
est: -17.80M (+53,268.6%)
|
| Net Income |
2.80B
|
| SGA |
24.13B
est: 28.92M (+83,354.9%)
|
| EPS |
56.00
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex Healthcare 266420.KS | 0.26% | 118.8K | 0.09% |
| 2 | Samsung Kodex Fn Growth ETF 325010.KS | 0.01% | 14.1K | 0.30% |
| 3 | Schwab International Small-Cap Equity ETF SCHC | 0.01% | 378.5K | 0.06% |
| 4 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 842.8K | 0.06% |
| 5 | Vanguard FTSE Pacific ETF VPL | 0.00% | 255.3K | 0.07% |
| 6 | Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO | 0.00% | 4.3K | 0.22% |
| 7 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 30.7K | 0.46% |
| 8 | Vanguard ESG International Stock ETF VSGX | 0.00% | 53.4K | 0.10% |
| 9 | Vanguard FTSE Developed All Cap ex North America Index ETF VIU.TO | 0.00% | 56.3K | 0.23% |
| 10 | Vanguard FTSE Developed All Cap ex North America Index ETF (CAD-hedged) VI.TO | 0.00% | 4.9K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jei-Man Ryu | CEO & Inside Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 019170.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
